Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

McKinsey
Harvard Business School
Baxter
AstraZeneca
Mallinckrodt
Johnson and Johnson

Last Updated: September 24, 2022

Patent: 10,012,654


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Summary for Patent: 10,012,654
Title:Biomarkers in inflammatory bowel disease
Abstract: The present invention provides a method of determining whether a patient with inflammatory bowel disease (IBD) and who has been treated with anti TNF.alpha. therapy is in immunological remission (IR), said method comprising determining the level of a cytokine selected from TNF.alpha., IL-17 and IFN-y in a Gl mucosal sample from said patient. Also provided are methods of prognosis and treatment using said method of determination, in particular discontinuing treatment if said patient is in IR and continuing treatment if said patient is not in IR.
Inventor(s): Florholmen; Jon (Tromso, NO), Olsen; Trine (Tromso, NO), Rismo; Renathe (Tromso, NO), Goll; Rasmus (Tromso, NO), Cui; Guanglin (Tromso, NO)
Assignee: UNIVERSITY OF TROMSO (Tromso, NO)
Application Number:14/653,750
Patent Claims:see list of patent claims

Details for Patent 10,012,654

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Janssen Biotech, Inc. REMICADE infliximab For Injection 103772 08/24/1998 See Plans and Pricing 2032-12-21
Abbvie Inc. HUMIRA adalimumab Injection 125057 12/31/2002 See Plans and Pricing 2032-12-21
Abbvie Inc. HUMIRA adalimumab Injection 125057 02/21/2008 See Plans and Pricing 2032-12-21
Abbvie Inc. HUMIRA adalimumab Injection 125057 04/24/2013 See Plans and Pricing 2032-12-21
Abbvie Inc. HUMIRA adalimumab Injection 125057 09/23/2014 See Plans and Pricing 2032-12-21
Abbvie Inc. HUMIRA adalimumab Injection 125057 11/23/2015 See Plans and Pricing 2032-12-21
Abbvie Inc. HUMIRA adalimumab Injection 125057 03/09/2016 See Plans and Pricing 2032-12-21
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKinsey
McKesson
Mallinckrodt
AstraZeneca
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.